Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Philogen SpA ( (IT:PHIL) ).
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 4,000 shares from December 1 to December 5, 2025, at an average price of Euro 22.9250 per share, totaling Euro 91,700. This buyback is part of a broader program approved earlier in the year, with the company having acquired a total of 35,947 shares since its inception. The move is likely aimed at consolidating ownership and potentially enhancing shareholder value, reflecting the company’s strategic financial management.
The most recent analyst rating on (IT:PHIL) stock is a Hold with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating high-mortality diseases. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers. Philogen’s main therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumor masses while sparing healthy tissues. This approach, known as vascular targeting, is primarily used for oncological applications but has potential for other diseases, such as chronic inflammatory conditions.
Average Trading Volume: 25,142
Technical Sentiment Signal: Strong Buy
Current Market Cap: €684.3M
For an in-depth examination of PHIL stock, go to TipRanks’ Overview page.